Bryan Pucik, MD
Family Medicine · Mankato, MNNPI 1073592077
Payments from drug & device makers
Across 40 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$52
- Radius Health, Inc.$48
- Philips North America LLC$33
- Exact Sciences$32
- Lundbeck LLC$32
- Amgen$32
- plus $360 from 22 others
What the payments were for
- Food & beverage$588100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 3 | $52 |
| Radius Health, Inc. | 2 | $48 |
| Philips North America LLC | 3 | $33 |
| Exact Sciences | 2 | $32 |
| Lundbeck LLC | 2 | $32 |
| Amgen | 2 | $32 |
| Johnson & Johnson | 2 | $29 |
| Boehringer Ingelheim | 2 | $26 |
| Ironwood Pharmaceuticals, Inc | 2 | $24 |
| Abbott | 1 | $23 |
| Melinta Therapeutics, LLC | 2 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Electromed, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| GSK | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Corium, LLC | 1 | $13 |
| AbbVie | 1 | $13 |
| AstraZeneca | 1 | $13 |
| Bayer | 1 | $12 |
| Sobi, Inc | 1 | $11 |
How this compares
$588 in reported general payments places this provider in the 90th percentile of 1,162 family medicine providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 82 | $91,534 |
| EliquisApixaban | 69 | $75,507 |
| Dupixent SyringeDupilumab | 11 | $49,227 |
| FarxigaDapagliflozin Propanediol | 50 | $47,901 |
| JardianceEmpagliflozin | 40 | $47,625 |
| TrulicityDulaglutide | 23 | $45,974 |
| MounjaroTirzepatide | 31 | $36,618 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $22,732 |
| LinzessLinaclotide | 24 | $19,792 |
| XareltoRivaroxaban | 20 | $19,244 |
| DuleraMometasone/Formoterol | 13 | $5,673 |
| Omeprazole | 277 | $4,247 |
| Levothyroxine Sodium | 271 | $4,011 |
| Atorvastatin Calcium | 281 | $3,558 |
| Lisinopril | 347 | $3,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $14 | $82,59254 claims |
| PfizerEliquis | $16 | $75,50769 claims |
| AstraZenecaFarxiga | $13 | $47,90150 claims |
| Boehringer IngelheimJardiance | $26 | $47,62540 claims |
| GSKTrelegy Ellipta | $15 | $22,73226 claims |
| AbbVieLinzess | $13 | $19,79224 claims |
| Johnson & JohnsonXarelto | $29 | $19,24420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,162 family medicine providers in Minnesota.
Other family medicine in Mankato
- John BensonMankato$498K
- Katie ThompsonMankato$91K
- Jeffrey PetersonAda$3.6M
- Melissa ChoiSt Louis Park$825K
- Amanda LovoldSt Cloud$387K
- Robert MarshMinnetonka$300K
- Jolene BergEdina$250K
- Allan LuistroMoorhead$225K
- Mathew StaymanEast Grand Forks$220K
- Pamela NollMinneapolis$178K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.